AMRX - Amneal Q1 topline misses maintains FY forecast

Amneal Pharmaceuticals (AMRX) posted first-quarter revenue that fell short of Wall Street estimates, partly hurt by decreased influenza activity during the period, and maintained its full-year forecast.Revenue during the quarter fell 1% to $493.1M, due to the higher customer purchases at the onset of the COVID-19 pandemic in the prior-year quarter.The company's topline pressure was partially offset by strong new Generics product launches and continued growth in its Specialty and AvKARE business segments.2021 Guidance: Net revenue between $2.1B - $2.2B; Adjusted diluted EPS between $0.70 - $0.85; Capital expenditures between $60M - $70M.Net income attributable to Amneal was $7M in the first quarter of 2021 compared to $115M last year, when the company had a discrete tax benefit of $110M from the Coronavirus Aid, Relief and Economic Security Act.The company posted adjusted quarterly profit of $0.20, beating analysts' estimate by 2 cents.Shares down nearly 1% premarket.Previously (May 7): Amneal Pharmaceuticals EPS beats by $0.02, misses

For further details see:

Amneal Q1 topline misses, maintains FY forecast